#3056
Multi-Omic Characterization and Evolution of Neuroendocrine Neoplasm Organoids
Introduction:
Molecular characterizations of neuroendocrine neoplasm (NENs) have unveiled candidate alterations associated with aggressiveness and suggested that the molecular link between neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) might be subtler than initially thought. For example, we have recently unveiled a new entity of pulmonary carcinoids (supra-carcinoids) with carcinoid-like morphology yet the molecular and clinical features of large cell neuroendocrine carcinoma (LCNEC). Testing hypotheses to explain aggressiveness and the possibility of progression or transition from NET to NEC through the accumulation of genetic anomalies requires in vitro and in vivo experimental models.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Foll M
Authors:
Alcala N,
Dayton T,
Mangiante L,
Delhomme T,
Tabone-Egling S,
Keywords:
organoids,
omics,
evolution,
lung,
pancreas,
bioinformatics,
#2944
Soluble ST2 (sST2) Levels in the Management of Carcinoid Heart Disease in Patients with Neuroendocrine Cancer
Introduction:
The identification of a sensitive biomarker to detect the presence and severity of carcinoid heart disease could allow more selective use of clinical and echocardiographic screening. ST2 is a protein belonging to the family of interleukin 1 receptors, present both in the isoform of transmembrane (ST2L) and in the soluble one (sST2). sST2 blocks the anti-inflammatory, anti-hypertrophic, and anti-fibrotic effects of cytokine IL-33 on the myocardium and recent studies have shown that sST2 levels increase in the blood of patients diagnosed with heart failure.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
Salvatici M,
Zorzino L,
Fabiani I,
Cardinale D,
Fazio N,
Keywords:
sST2,
Biomarkers,
Carcinoid Heart Disease,
#2849
PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction:
The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Bodei L
Authors:
Bodei L,
Kidd M,
Singh A,
van der Zwan W,
Severi S,
Keywords:
biomarker,
PRRT,
prediction,
NETest,
PPQ,
CgA,
personalized medicine,
#2216
Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker
Introduction:
We have developed a blood-based tool (gene expression analysis and tumor grade) for predicting PRRT efficacy.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Bodei L
Authors:
Bodei L,
Kidd M,
van der Zwan W,
Singh A,
Severi S,
Keywords:
Biomarker,
carcinoid,
PRRT,
prediction,
therapy,
efficacy,
stratification,
